## Introduction

Arterial stents are medical devices that have revolutionized the treatment of coronary artery disease. They serve to reopen the occluded vessel that has become narrowed as a result of atherosclerosis. Atherosclerosis is a common degenerative disease that affects coronary, carotid and other peripheral arteries in the body. Now, it is standard to use the types of stents that gradually release anti-proliferative/anti-inflammatory drugs into the arterial wall to inhibit the cell proliferation that causes the development of restenosis (re-narrowing). The bare metal stents (BMS^{s}), while revolutionary at the time, were soon rendered unsatisfactory due to their inability to prevent in-stent restenosis. The next wave of drug-eluting stents (DES^{s}) consists of a supporting metallic wired scaffold coated with a polymer film that encapsulates the therapeutic drug aimed at preventing hyperplasia of the smooth muscle cells (SMC^{s}) that is responsible for restenosis.

In order to control the release rate, the coating may include a rate-limiting barrier. To ensure effective performance of DES, both the stent geometry and coating design need to be optimized so that therapeutic levels of drug are delivered to the arterial wall for the required period of time.^{1}^{,}^{2} The success of an anti-proliferative drug therapy from DES depends on the amount of drug eluted from the stent, accumulation of the drug, and drug binding to cells in the arterial wall. Even though DES are now the primary choice of percutaneous coronary interventions (PCI^{s}) for millions of patients, many questions still remain unanswered regarding their longevity and safety.

Although it was not the intention of this article to provide a review of the previously published models, it will describe some experimental studies which have been carried out in the recent past in order to quantify the capability of this device to reduce the in-stent restenosis rate after stent implantation.^{3}^{–}^{5} The behavior of heparin in explanted arteries allows for the presence of binding site changes along the transmural direction, being higher in the endothelium and lower in the adventitia, as studied by Lovich *et al*.^{3} In the experimental study by Migliavacca *et al*.,^{6} the pattern of DES drug release in the vascular wall was considered using a single species approach along with a partition coefficient approach to relate the free and the bound drug concentrations. Borgi *et al*.^{7} focused on the inclusion of reversible binding leading to delayed release and that the erosion of polymer affects the drug release from a single strut. Horner *et al*.^{8} appear to be one of the first groups to provide a three-dimensional reaction-diffusion-convection process of a two-species drug delivery model, including reversible binding sites in a realistic geometry; their model predicted that a single species drug delivery model cannot accurately predict the distribution of the bound drug. Ferreira *et al*.^{9} considered a series of nonlinear binding models to describe the degradation of a poly-L-lactic acid stent coating into lactic acid and oligomers.

Although a large number of mathematical models are available to describe drug transport and its binding to arterial tissue sites, only a few (*v.i.z.* Tzafriri *et al*.^{10}) considered a nonlinear saturable binding model; later, Bozsak *et al*.^{11}^{,}^{12} also considered this. The model from the latter included two phases of drug in the tissue: free and bound. However, it is well established that in addition to binding to specific receptors (SR), there is also the occurrence of nonspecific binding caused by association of drug with membrane constituents or by trapping of the drug in the extracellular medium.^{13} Most recently, Tzafriri *et al*.^{14} and McGinty *et al*.^{15} included two equations for drug binding in arterial tissue, namely one for specific binding to receptors and another for nonspecific binding to general extracellular matrix (ECM) sites. Thus, it appears that there are three phases in the tissue, comprising two bound (SR and ECM) and one free.

The main aim of this investigation was to extend the aforementioned work^{14}^{,}^{15} with a two-species model of specific and nonspecific saturable binding in the arterial wall at different phases following drug transport eluted from three struts, where the transport of free drug is governed by a convection-diffusion-reaction process and that of bound drugs (SR and ECM) by a reaction process only. A simple time-dependent release kinetics is implemented on the surface of the struts.^{16} The transport of drugs within the arterial tissue is controlled by arterial properties like porosity and tortuosity. At the time of implantation of an endovascular DES, its major impact is on the structure of the arterial wall, which eventually influences the overall rates of diffusion through tissues. The effective diffusivity of a porous wall is supposed to depend on two factors, such as porosity and tortuosity—these parameters regulate the free diffusivity of the drug eluted from struts.^{17} As such, the present study also deals with the effects of porosity and tortuosity on the diffusivity of drug.

## Materials and methods

Please refer to Table 1 for nomenclature.

Nomenclature | |
---|---|

L | Dimensionless length of the artery |

c_{s} | Initial drug concentration on the stent |

V_{wall} | Transmural filtration velocity |

r | Dimensional radial coordinate |

r | Dimensionless radial coordinate |

z | Dimensional axial coordinate |

z | Dimensionless axial coordinate |

t | Dimensional time |

t | Dimensionless time |

c_{f} | Dimensional concentration of free drug |

c_{f} | Dimensionless concentration of free drug |

c_{bECM} | Dimensional concentration of ECM-bound drug |

c_{bECM} | Dimensionless concentration of ECM-bound drug |

c_{bSR} | Dimensional concentration of SR-bound drug |

c_{bSR} | Dimensionless concentration of SR-bound drug |

c_{bECM}^{max} | ECM binding site density |

c_{bSR}^{max} | Receptor density |

B_{M} | Total tissue binding capacity |

K_{d}^{ECM} | ECM binding on-rate |

k_{on}^{SR} | Receptor binding on-rate |

K_{d} | Equilibrium association constant |

K_{d}^{ECM} | ECM dissociation constant |

K_{d}^{SR} | Receptor dissociation constant |

D_{free} | Free drug diffusivity |

D_{eff} | Effective diffusivity of free drug |

D_{T} | True drug diffusivity of arterial wall |

D_{T}^{ECM} | True drug diffusivity of ECM sites |

D_{T}^{SR} | True drug diffusivity of SR sites |

Pe_{T} | Non-dimensional Peclet number |

Pe_{1} | Non-dimensional Peclet number |

Pe_{2} | Non-dimensional Peclet number |

Da_{1} | Dimensionless Damköhler number |

Da_{2} | Dimensionless Damköhler number |

### Geometric model

The computational domain is comprised of a long axial section of length *L* and the wall thickness is taken to be 10 times the strut height (δ). The axis of symmetry is taken along the centerline of the artery (cf. Fig. 1). The volume-averaged molar concentration of free drug is denoted by *c** _{f}*, the volume-averaged molar concentration of bound drug that is bound to nonspecific general ECM sites in the tissue is referred to as ECM-bound drug and denoted by

*c*

*, and the volume-averaged molar concentration of bound drug that is bound to specific receptors is referred to as SR-bound drug and denoted by*

_{bECM}*c*

*. The inter-conversion of drug between the unbound plasma phase and the bound phase of tissue binding sites is controlled by a second-order nonlinear reversible saturable chemical reaction. The transport of free drug eluted from struts is governed by unsteady convection-diffusion-reaction process (Eq. 1),*

_{bSR}^{18}

^{–}

^{20}the ECM-bound drug is represented by unsteady reaction process (Eq. 2),

^{21}and that of the SR-bound drug is represented by unsteady reaction process (Eq. 3).

^{22}Symmetry boundary conditions for both the free and both of the bound drugs are applied at the proximal (

*Γ*) and the distal (

_{ti}*Γ*) walls (Eq. 4).

_{to}^{23}Impermeable boundary condition for both of the bound drugs is assumed at the perivascular wall (

*Γ*), lumen-tissue (

_{tp}*Γ*) and strut-tissue (

_{bt}*Γ*) interfaces (Eq. 5). For the free drug, a perfectly sink condition is imposed at the perivascular end (Eq. 6). Since a proper boundary condition for the free drug at lumen-tissue interface (

_{st}*Γ*) is not readily apparent, two opposing extremes consider either that flowing blood is extremely efficient at washing out mural-adhered drug, modelled as a zero-concentration interface condition, or mural-adhered drug is insensitive to flowing blood, modelled as a zero-flux boundary condition (Eq. 7).

_{bt}^{24}Instead of modelling a uniform release of drug from struts, a simple time-dependent release kinetics (Eq. 8)

^{25}

^{,}

^{26}is assumed.

### Governing equations and boundary conditions

Therefore, the governing equations of the drug transport of free, ECM-bound (saturable binding to general ECM sites) and SR-bound (saturable binding to specific receptors) in the arterial wall are respectively represented in a two-dimensional (2D) Cartesian coordinate system in the following manner:

Where *t**r**c** _{f}* is the molar concentration of free drug per unit tissue volume,

*c*

*and*

_{bECM}*c*

*are the molar concentrations of ECM- and receptor-bound drug respectively,*

_{bSR}*c*

_{bECM}^{−max}and

*c*

_{bSR}^{−max}denote the local molar concentration of ECM and receptor drug binding sites respectively,

*k*and

_{on}^{ECM}*K*are the respective binding on-rate constants,

_{on}^{SR}*K*and

_{d}^{ECM}*K*are the respective equilibrium dissociation constants, and

_{d}^{SR}*V*is its transmural convective velocity. Here,

_{wall}*D*is the transmural true diffusivity of the drug which can be written as

_{T}^{17}

^{,}

^{27}

Here, *ε _{w}* and

*τ*are the porosity and the tortuosity of the wall material respectively,

_{w}*D*and

_{free}*D*are the coefficients of free and effective diffusivity respectively,

_{eff}*B*and

_{M}*K*are the net tissue binding capacity and equilibrium association constant respectively.

_{d}The symmetry boundary conditions (free, ECM-bound and SR-bound drug) are imposed on the proximal (*Γ _{ti}*) and the distal (

*Γ*) walls as

_{to}The impermeable boundary condition for both of the bound drugs (ECM-bound and SR-bound) is assumed at the perivascular wall (*Γ _{tp}*), lumen-tissue (

*Γ*) and strut-tissue (

_{bt}*Γ*) interfaces as

_{st}At the perivascular wall (*Γ _{tp}*), a perfectly sink condition

^{4}

^{,}

^{11}is imposed for the free drug (

*c*

*f*) as

At the lumen-tissue interface (*Γ _{bt}*) a proper boundary condition for the free drug is not readily apparent. Considering two opposing extremes, either the flowing blood is extremely efficient at washing out mural-adhered drug, modelled as a zero-concentration interface condition, or mural-adhered drug is insensitive to flowing blood, modelled as zero-flux boundary condition as

As the dimension of stent struts is thin with respect to the arterial wall thickness, so their actual geometry is neglected and approximate the drug eluting stent using an equivalent phantom surface that elutes a defined drug load to the arterial wall (Fig. 1). Elution from the phantom surface is modelled by a simple time-dependent release kinetics as follows

*c*is the initial drug concentration on the stent, and

_{s}*λ*

All the variables and parameters are now made dimensionless to obtain well-behaved computations in the following manner:

Under these assumptions, the above equations (1–8) take their respective non-dimensional forms as follows:

where the Peclet numbers (*Pe _{T}*,

*Pe*

_{1}and

*Pe*

_{2}), the Damköhler numbers (

*Da*

_{1}and

*Da*

_{2}), the scaling parameters (

*α*,

*α*

_{1},

*β*and

*β*

_{1}) and dimensionless drug release rate (

*λ*) are defined respectively as:

*K*(

_{d}^{ECM}*k*/

_{r}^{ECM}*k*) and

_{on}^{ECM}*K*(

_{d}^{SR}*k*/

_{r}^{SR}*k*) are, respectively, the equilibrium dissociation constants of the ECM-bound drug and the SR-bound drug,

_{on}^{SR}*k*and

_{r}^{ECM}*k*are the dissociation (backward) rate constant of ECM and receptor drug binding sites in the arterial tissue respectively. Here,

_{r}^{SR}*D*and

_{T}^{ECM}*D*are, respectively, the true diffusivities of the ECM-bound drug and the SR-bound drug.

_{T}^{SR}### Solution procedure

The governing equations (9–11) representing the transport of free, ECM-bound and SR-bound drugs were solved numerically using a finite-difference scheme by applying the time-dependent release kinetics and boundary conditions (12–16). For this type of grid alignment, the concentrations for free, ECM-bound and SR-bound drugs were calculated at the cell centers (Fig. 2). The discretization of the time derivative term was based on the first order accurate two-level forward time-differencing formula, while the convective term in the equations is accorded with a hybrid formula, consisting of central differencing and second order up-winding. The diffusive terms are, however, discretized by a second order accurate three-point central difference formula. In order to have second order spatial accuracy of the boundary conditions, some fictitious grid points outside the physical domain were considered. To achieve the steady state criterion, one needs to perform at least 8,00,000 iteration steps for the marker and cell (MAC) scheme. Steady state is achieved when the convergence criterion for concentration is 10^{−6} for each drug form. Interested readers are referred to Saha *et al*.^{28} for the detailed numerical procedure.

## Results and discussion

For the purpose of numerical computation of the quantities of physiological significance, the computational domain has been confined to a finite non-dimensional arterial length of 50. For this computational domain, solutions are computed with grid sizes 501 × 101 for *δt* = 0.0001.

Based on the numerical values in Table 2^{10}^{,}^{14}^{,}^{17}^{,}^{19}^{,}^{22}^{,}^{23}^{,}^{27}^{,}^{29}^{–}^{39} of the model parameters, an extensive quantitative analysis has been performed through graphical representations, the results are presented in Figures 3–14. These are representative of a first-generation DES (Cypher) which elutes the drug sirolimus. The radial locations-variant normalized concentration profiles for free drug, ECM-bound drug and SR-bound drug concentrations in the tissue for three different times have been shown in Figure 3a–c respectively. It was observed from the figures that with increasing time, the drug masses (free, ECM-bound and SR-bound) decrease (at *z* = 21.5). The rate of decrease for the free drug is faster than the ECM-bound drug, whereas the SR-bound drug is slower than the ECM-bound drug. As a result, the drug enters the arterial wall (at *r* = 15) in the free phase and is rapidly bound to both ECM and SR binding sites. The free and ECM-bound drug concentration profiles rise to a peak (shown in Fig. 3d) before decaying with time as the drug traverses through the tissue, becomes bound to SR in the binding phase, and is absorbed at the adventitial boundary (*r* = 25).

Parameter | Value with unit | Reference |
---|---|---|

δ | 10^{−4} m | ^{19}^{,}^{29}^{,}^{37} |

C_{S} | 10^{−2} mol m^{−3} | ^{35} |

V_{wall} | 5.8 × 10^{−8} m s^{−1} | ^{31}^{,}^{36} |

c_{bECM}^{max} | 3.63 × 10^{−1} mol m^{−3} | ^{10} |

c_{bSR}^{max} | 3.3 × 10^{−3} mol m^{−3} | ^{14} |

B_{M} | 1.3 mol m^{−3} | ^{27} |

K_{on}^{ECM} | 2.0 [mol m^{−3} s]^{−1} | ^{10} |

K_{on}^{SR} | 8.0 × 10^{2} [mol m^{−3} s]^{−1} | ^{38} |

K_{d} | 0.136 mol m^{−3} | ^{27} |

K_{d}^{ECM} | 2.6 × 10^{−3} mol m^{−3} | ^{10} |

K_{d}^{SR} | 2.0 × 10^{−5} mol m^{−3} | ^{22} |

k_{r}^{ECM} | 5.2 × 10^{−3} s^{−1} | ^{14} |

k_{r}^{SR} | 1.6 × 10^{−3} s^{−1} | ^{14} |

D_{free} | 3.65 × 10^{−12} m^{2} s^{−1} | ^{23}^{,}^{32} |

λ | 10^{−5} s^{−1} | ^{33}^{,}^{34} |

ε_{w} | 0.787 | ^{17} |

γ_{w} | 1 | ^{30}^{,}^{39} |

τ_{w} | 1.333 | ^{17} |

Although the free and ECM-bound phase profile shapes are similar, drug concentrations within the SR-bound phase are greater than in the ECM-bound phase, which in turn is greater than the free drug concentrations. Within the time *t* = 10, the SR-bound drug spanning 30% the thickness of the tissue is saturated; these remain saturated for the duration of the time *t* = 200 studied (Fig. 3c). The remaining SR sites become saturated in the subsequent times and they too remain at saturation levels for the duration of the times *t* = 300. In Figure 3d, the temporal variation of normalized mean drug concentration profiles reveals that the drug binding in the SR-bound phase is higher than the drug binding in the ECM-bound phase. Therefore, the results of this study demonstrate that drug delivered to the arterial wall from the stent is too low to occupy a large proportion of ECM binding sites, yet is high enough to saturate SR binding sites. This agrees with Tzafriri *et al*.^{14}

The time-variant concentration profiles for free drug, ECM-bound drug and SR-bound drug concentrations in the tissue for different radial locations are shown in Figure 4a–c respectively. It was observed from these figures that with increasing radial locations (from lumen-tissue interface), the drug masses (free, ECM-bound and SR-bound) decrease (at *z* = 21.5). The characteristics of the graphs are quite similar, as anticipated, with the binding and unbinding processes taking place simultaneously. Moreover, at the interface, it has been observed that the concentration of drug attains its maximum value for all time, as expected.

Distributions of normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations over the entire period of time for different values of the Peclet number *P _{eT}* are presented in Figure 5a–d respectively. It is observed that in each case the drug mass is first increasing, up to some upper bound, and then decreasing asymptotically. Evidently,

*P*, depending on

_{eT}*D*, again

_{T}*D*depends on

_{T}*D*, increases with a decrease of the porosity (

_{eff}*ε*) of the arterial wall (as the porosity decreases, the effective as well as true diffusivity does decrease), and also with an increase of the tortuosity (

_{w}*τ*) of the arterial wall (as the tortuosity increases, the effective diffusivity as well as true diffusivity does decrease) (keeping

_{w}*D*fixed). It is observed from these figures that all the mean drug (free, ECM-bound, SR-bound and total) concentrations decrease with decreasing porosity and increasing tortuosity of the arterial wall (

_{free}*i.e.*increase of the Peclet number (

*Pe*)).

_{T}The influence of scaling parameter *Da*_{1}/*Pe*_{1} on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue are displayed in Figure 6a–d respectively over a stipulated period of time. Evidently, *Da*_{1}/*Pe*_{1}, depending on *k _{on}^{ECM}* and

*c*(keeping

_{bECM}^{max}*δ*and

*V*fixed), increases/decreases with an increase/decrease in the ECM binding site density (

_{wall}*c*) and also with an increase/decrease of ECM binding on-rate (

_{bECM}^{max}*k*). It has been observed that with increasing ECM binding site density and ECM binding on-rate (

_{on}^{ECM}*i.e.*increase of

*Da*

_{1}/

*Pe*

_{1}), the mean drug (free, SR-bound and total) concentrations decrease. But, the mean ECM-bound drug concentration increases with increasing ECM binding site density and ECM binding on-rate (

*i.e.*increase of

*Da*

_{1}/

*Pe*

_{1}).

The influence of scaling parameter *Da*_{2}/*Pe*_{2} on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue are displayed in Figure 7a–d respectively over a stipulated period of time. Evidently, *Da*_{2}/*Pe*_{2}, depending on *k _{on}^{SR}* and

*c*(keeping

_{bSR}^{max}*δ*and

*V*fixed), increases/decreases with an increase/decrease in the receptor binding site density (

_{wall}*c*) and also with an increase/decrease in receptor binding on-rate (

_{bSR}^{max}*k*). It has been observed that with increasing receptor binding site density and receptor binding on-rate (

_{on}^{SR}*i.e.*increase of

*Da*

_{2}/

*Pe*

_{2}), the mean drug (free and ECM-bound) concentrations decrease. But, the mean SR-bound and total drug concentrations increase with increasing receptor binding site density and receptor binding on-rate (

*i.e.*increase of

*Da*

_{2}/

*Pe*

_{2}). It was also observed in Figure 7a–d that the effects of

*Da*

_{2}/

*Pe*

_{2}on SR-bound and total drugs are more sensitive than free and ECM-bound drugs.

The results in Figure 8a–d, respectively, exhibit the influence of scaling parameter *α* on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue over the entire period of time. Evidently, α, depending on *c _{bECM}^{max}*, increases with a decrease in the ECM binding site density (

*c*) (keeping

_{bECM}^{max}*c*fixed). It is an obvious observation that if the ECM binding site density decreases (

_{s}*i.e.*the scaling parameter α increases) then all the mean drug (free, ECM-bound, SR-bound and total) concentrations increase.

The results in Figure 9a–d, respectively, exhibit the influence of scaling parameter *α*_{1} on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue over the entire period of time. Evidently, *α*_{1}, depending on *K _{d}^{ECM}*, increases with an increase of the dissociation (backward) rate constant (

*K*) in the ECM binding site and also with a decrease in ECM binding on-rate (

_{r}^{ECM}*k*) (keeping

_{on}^{ECM}*c*fixed). It is an obvious observation that if the ECM binding on-rate decreases and dissociation (backward) rate constant in the ECM binding site increases (

_{s}*i.e.*the scaling parameter

*α*

_{1}increases) then the mean drug (free, SR-bound and total) concentrations increase. But, the mean ECM-bound drug concentration decreases with decreasing ECM binding on-rate and increasing dissociation (backward) rate constant in the ECM binding site (

*i.e.*increase of scaling parameter

*α*

_{1}).

The results, shown in Figure 10a–d, respectively, project the influence of scaling parameter *β* on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue over the entire period of time. Evidently, *β*, depending on *c _{bSR}^{max}*, increases with a decrease in the receptor binding site density (

*c*) (keeping

_{bSR}^{max}*c*fixed). It is an obvious observation that if the receptor binding site density decreases (

_{s}*i.e.*the scaling parameter

*β*increases) then all of the mean drug (free, ECM-bound, SR-bound and total) concentrations increase.

The influence of scaling parameter *β*_{1} on the normalized mean free drug, mean ECM-bound drug, mean SR-bound drug and mean total drug concentrations in the arterial tissue are displayed in Figure 11a–d respectively over a stipulated period of time. Evidently, *β*_{1}, depending on *K _{d}^{SR}*, increases with an increase in the dissociation (backward) rate constant (

*K*) in the receptor binding site and also with a decrease in receptor binding on-rate (

_{d}^{SR}*K*) (keeping

_{on}^{SR}*c*fixed). It was observed that with decreasing receptor binding on-rate and increasing dissociation (backward) rate constant in the receptor binding site (

_{s}*i.e.*increase of

*β*

_{1}), the mean drug (free and ECM-bound) concentrations increase. But, the mean SR-bound and total drug concentrations decrease with decreasing receptor binding on-rate and increasing dissociation (backward) rate constant in the receptor binding site (

*i.e.*increase of scaling parameter

*β*

_{1}). It was also observed from Figure 11a–d that the effects of scaling parameter

*β*

_{1}on SR-bound and total drugs are more sensitive than free and ECM-bound drugs.

Finally, in Figure 12a–c, respectively, the displayed spatial distribution of free, ECM-bound and SR-bound drug concentration may again clearly justify the reduction of late lumen loss at the distal part of the arterial tissue, which again validates the findings of Balakrishnan *et al*.^{29} The spatial patterns for free, ECM-bound and SR-bound drug concentration in Figure 13a–c, respectively, clearly establish our findings further for the zero-concentration interface condition and constant release kinetics. In the Figure 14a–c, respectively, the spatial distribution of free, ECM-bound and SR-bound drug concentration for the zero-flux interface condition and time-dependent release kinetics is displayed.

## Conclusions

In the present work, a novel analytical closed-form solution of a 2D axi-symmetric model of drug transport eluted from a coronary DES is proposed and focused on the reversible and saturable binding processes in the vascular tissue. The model is based on a single-layered homogeneous multiple-phase system where a system of partial differential equations describes both the dissolution and diffusion processes in the polymeric layer as well as diffusion, convection and reaction in the tissue. The closed-form solution has been established by using the MAC method.

The salient observations of the above findings are the following:

## Future research directions

Application of this framework to idealized configurations of arteries stented with a DES yielded some general guidelines for future DES design, especially concerning strategies for the effective elution of the anti-proliferative drug from the stent and its efficacy. Despite these very useful results, many improvements can be envisaged in future models. Limitations of the current model are that the model geometry is 2D axi-symmetric, the considered stent is idealized having three stent struts, and the model is limited to a straight vessel segment. Although the target zone is an atherosclerotic plaque, this consideration has been disregarded here. Inclusion of realistic plaque with anisotropic tissue properties, together with the varying diffusivity of eluted drug within the target lesion, may be the scope of future research.

It will be important to eventually perform the simulations on more realistic three-dimensional geometries where the detailed structure of the stent design is to be taken into account. Based upon the present model validation, the model can be evolved further with the incorporation of several factors, depending on the objectives of the drug release phenomena in various situations, for designing future research in this direction by utilizing the present knowledge of the system.

## Medical benefits

Mathematical modelling and numerical simulation are indispensable tools when clinical investigation and/or animal studies are expensive, and in some cases, cumbersome as well. A mathematical model can give us an idea of how an underlying mechanism plays a surrogative role on cardiovascular intervention. The present study gives an overview on the release kinetics and also the binding of sirolimus drug eluted from a coronary stent which helps, certainly, the clinician to estimate the effectiveness of delivery and also the efficacy of drug. Although the present study is an idealized one, it will give an idea to the manufacturer in designing next generation of DES. We point out that the results presented here are for the simulated case of sirolimus release and absorption from the Cypher stent.

The significant influence of estimated parameters on the drug masses has been shown graphically, which establishes the strong fact that by altering the parameters, various means of drug release control can be achieved according to the patients’ needs. Various conclusions can be drawn from the dynamical behavior of the present model study. It is worth noting that as the drug needs a much longer time in the tissue to get absorbed completely, its effect will certainly persist for a long time before the same drug is administered subsequently. This approach may also be applied in any form to other parts of the human body, provided the system does not have major clinical complexity.

## Abbreviations

- 2D:
two-dimensional

- BMS:
bare metal stents

- DES:
drug-eluting stents

- ECM:
extracellular matrix

- MAC:
marker and cell

- PCI:
percutaneous coronary interventions

- SDR:
specific drug binding

- SER:
stent elution rate

- SMC:
smooth muscle cells

- SR:
specific receptors

## Declarations

### Acknowledgement

The author gratefully acknowledges the careful scrutiny and suggestions of the learned reviewers. The author also expresses his gratitude to Professor Prashanta Kumar Mandal, Department of Mathematics, Visva-Bharati University, Santiniketan-731235, West Bengal, India, for fruitful discussions about this paper and for useful support in some numerical tasks.

### Conflict of interest

The author declares that no conflict of interest exists.

### Authors’ contributions

RS is the sole author.